27 August 2020

Advanced Technology International (ATI)
ATTN: Contracts Manager
315 Sigma Drive
Summerville, SC 29486

Dear Contracts Manager:

SUBJECT: Project Approval Letter (PAL) for 20-12-COVID19-Diagnostics-046 for “ICU-Grade Wearable Sensors with to Diagnose and Detect Pre and Very Early Symptomatic COVID-19 Infection” to Sibel, Inc., PAL Version 1

REF: Revised Request for Project Approval from ATI dated 14 August 2020 for 20-12-COVID19-Diagnostics-046 under OTA W81XWH-15-9-0001

EGS#: MT20012.046

In support of the U.S. Army Medical Research and Development Command (USAMRDC), ATI, on behalf of the Medical Technology Enterprise Consortium (MTEC) issued Request for Project Proposal (RPP) number MTEC-20-12-COVID19-Diagnostics on 1 May 2020. Both current and prospective members of the MTEC submitted Enhanced White Papers in response to this RPP, in accordance with the terms of the RPP. Subsequently, the Government evaluated those Enhanced White Papers that passed the Government’s initial screening process in accordance with the stated evaluation criteria.

Based upon the evaluation of Sibel, Inc’s proposal (20-12-COVID19-Diagnostics-046) entitled, “ICU-Grade Wearable Sensors with to Diagnose and Detect Pre and Very Early Symptomatic COVID-19 Infection,” and ATI’s request for PAL (which includes the Statement of Work (SOW), inclusive of an acceptable milestone schedule), ATI is hereby authorized to issue a Research Project Award (RPA) to Sibel, Inc. for the subject initiative. This approval is contingent upon the provision of funding via a separate Other Transaction Agreement Task Order modification, W81XWH-20-9-0015-P00001. The Sponsor Office Technical Representative (SOTR) for this RPA is

The period of performance of the Research Project Award is 9 months. Note, however, that the period of performance within the Other Transaction Agreement Task Order, W81XWH-20-9-0015, includes additional time to account for the final negotiations between ATI and all performers included under the “Wearable Diagnostic for Detection of COVID-19 Infection”
SUBJECT: PAL for 20-12-COVID19-Diagnostics-046 for “ICU-Grade Wearable Sensors with \( \text{(b)(4)} \) to Diagnose and Detect Pre and Very Early Symptomatic COVID-19 Infection \( \text{(b)(4)} \) to Sibel, Inc., PAL Version 1

Task Order to finalize negotiations for the individual RPAs. This additional time is intended to align the end dates for the Task Order and RPAs.

Special Considerations

a. The Government has not identified any national security restrictions that apply to this RPA.

b. The following special research considerations are applicable to this award: use of human subjects and human anatomical substances. Approval from the MRDC Human Research Protections Office (HRPO) must be obtained prior to commencement of the tasks involving human subjects and human anatomical substances.

Data Rights

As stated in Sibel, Inc’s proposal entitled, “ICU-Grade Wearable Sensors with \( \text{(b)(4)} \) to Diagnose and Detect Pre and Very Early Symptomatic COVID-19 Infection \( \text{(b)(4)} \)”, all items except those listed in the following table will be delivered to the Government with Government Purpose Rights.

<table>
<thead>
<tr>
<th>Technical Data or Computer Software to be Furnished with Restrictions</th>
<th>Basis for Assertion</th>
<th>Asserted Rights Category</th>
<th>Name of Organization Asserting Restrictions</th>
<th>Task # Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \text{(b)(4)} )</td>
<td>( \text{(b)(4)} )</td>
<td>Limited</td>
<td>Sibel</td>
<td>1</td>
</tr>
<tr>
<td>( \text{(b)(4)} )</td>
<td>( \text{(b)(4)} )</td>
<td>Limited</td>
<td>Sibel</td>
<td>1</td>
</tr>
<tr>
<td>( \text{(b)(4)} )</td>
<td>( \text{(b)(4)} )</td>
<td>Limited</td>
<td>Sibel</td>
<td>1</td>
</tr>
</tbody>
</table>

Pre-Award Cost Authorization

The Agreements Officer has authorized pre-award costs for the RPA to Sibel, Inc. As the Pre-Award Cost Authorization (PACA) letter was fully executed between ATI and Sibel, Inc. on 08 July 2020, the Government agrees to pay allowable costs accrued in the performance of this RPA starting on this date (08 July 2020) through the end of the period of performance in an amount not to exceed $623,700.50. Additionally, the Agreements Officer authorized the allowance of costs incurred by \( \text{(b)(4)} \) as Cost Share (Anticipated Non-Federal Contribution) starting on this date (08 July 2020).
The total authorized value has been determined fair and reasonable and this proposal has been selected in accordance with the RPP evaluation criteria. The Agreements Officer documented the appropriate use of Section 815 prototype OTA authority. The total approved cost to the Government for this effort is Not-to-Exceed (NTE) $2,396,958.00 (note that the (b) (4) is inclusive of the Anticipated Non-Federal Contribution). At no time shall the Government’s obligation exceed the funding provided for this RPA.

<table>
<thead>
<tr>
<th>Government Project Funding</th>
<th>ATI Fixed Fee (Gov’t Funding)</th>
<th>Total Cost to the Government</th>
<th>Anticipated Non-Federal Contribution</th>
<th>Total Program Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,396,958.00</td>
<td>$0.00</td>
<td>$2,396,958.00</td>
<td>(b) (4)</td>
<td>(b) (4)</td>
</tr>
</tbody>
</table>

Sincerely,

THOMA 1267679009

Thomas L. Hood
Agreements Officer

Enclosed:
Statement of Work with Milestones